Monday, September 15, 2025

Latest

MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to develop R(-)-MDMA for treating symptoms related to autism spectrum disorder. The move also reflects the firm’s efforts to diversify its drug development pipeline, which currently includes studies on psychedelics and pain treatment.

In particular, the program aims to treat social anxiety and impairments in social functioning related to the disorder. The firm said there are no approved therapies for the core symptoms and “there remains a significant unmet need for novel therapies” to support people with the disorder.

“The compelling clinical efficacy of MDMA coupled with the unique pharmacological benefits of its R(-) enantiomer suggest that there is an enormous opportunity to bring this second generation psychedelic program to market with the potential for new clinical applications, novel treatment paradigms, and enhanced accessibility,” said MindMed CEO Robert Barrow.

The psychoactive drug MDMA — which contains two structurally unique enantiomers, R(-) and S(+) — is currently being developed to treat post-traumatic stress disorder. Data suggests that the R(-) enantiomer can maintain pro-social and empathogenic benefits while demonstrating fewer signs of stimulant activity, neurotoxicity, hyperthermia, and abuse liability. Hence, the firm said the profile of  R(-)-MDMA could have the potential for novel and more accessible delivery models and repeat dosing.

The biotech firm plans to initiate the clinical trials for the program in 2022, with plans to compare the MDMAs with different enantiomers: R(-)-MDMA, S(+)-MDMA, and R/S-MDMA.

Mind Medicine Inc. last traded at $3.00 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Mind Medicine Closes The Year Out With Further Management Departures

Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO...

Wednesday, December 29, 2021, 08:38:09 AM

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for...

Wednesday, May 26, 2021, 10:14:37 AM

JR Rahn: Using LSD To Treat Mental Health – The Daily Dive

For our Saturday edition of The Daily Dive, host Cassandra Leah sits down with that...

Saturday, March 20, 2021, 01:30:00 PM

Mind Medicine To Conduct $25.0 Million Bought Deal Financing

Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this...

Friday, October 9, 2020, 09:01:05 AM

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM